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Abstract
Background: 5-lipoxygenase (5-LO) catalyses the transformation of arachidonic acid (AA) into leukotrienes (LTs), which are
important lipid mediators of inflammation. LTs have been directly implicated in inflammatory diseases like asthma,
atherosclerosis and rheumatoid arthritis; therefore inhibition of LT biosynthesis is a strategy for the treatment of these
chronic diseases.
Methodology/Principal Findings: Analogues of caffeic acid, including the naturally-occurring caffeic acid phenethyl ester
(CAPE), were synthesized and evaluated for their capacity to inhibit 5-LO and LTs biosynthesis in human polymorphonuclear
leukocytes (PMNL) and whole blood. Anti-free radical and anti-oxidant activities of the compounds were also measured.
Caffeic acid did not inhibit 5-LO activity or LT biosynthesis at concentrations up to 10 mM. CAPE inhibited 5-LO activity (IC50
0.13 mM, 95% CI 0.08–0.23 mM) more effectively than the clinically-approved 5-LO inhibitor zileuton (IC50 3.5 mM, 95% CI
2.3–5.4 mM). CAPE was also more effective than zileuton for the inhibition of LT biosynthesis in PMNL but the compounds
were equipotent in whole blood. The activity of the amide analogue of CAPE was similar to that of zileuton. Inhibition of LT
biosynthesis by CAPE was the result of the inhibition of 5-LO and of AA release. Caffeic acid, CAPE and its amide analog were
free radical scavengers and antioxidants with IC50 values in the low mM range; however, the phenethyl moiety of CAPE was
required for effective inhibition of 5-LO and LT biosynthesis.
Conclusions: CAPE is a potent LT biosynthesis inhibitor that blocks 5-LO activity and AA release. The CAPE structure can be
used as a framework for the rational design of stable and potent inhibitors of LT biosynthesis.
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Introduction
5-lipoxygenase (5-LO), expressed in a number of myeloid and
lymphoid cells such as B cells, monocytes, neutrophils, eosinophils
and mast cells, is the key enzyme in the bioconversion of
arachidonic acid (AA) to leukotrienes (LTs) [1]. LTs are important
lipid mediators of inflammation that are involved in various
inflammatory diseases such as atherosclerosis [2], asthma [3] and
rheumatoid arthritis [4]. Studies have also demonstrated a
potential role for 5-LO in cancer since its overexpression is
observed in tissue samples from patients with prostate carcinoma
[5] and this enzyme is an important regulator of leukemia stem cell
development [6]. Consequently, the inhibition of the 5-LO
pathway has been studied as a therapeutic target for a number
of years (reviewed by [7]). The anti-asthmatic drug zileuton [8] is
the only 5-LO inhibitor approved and commercially available for
clinical use, but adverse effects including liver toxicity has limited
its use [9]. Another inconvenience of the drug is its pharmaco-
kinetic profile requiring dosing of up to 600 mg four times a day
[8,10]. Thus the search for alternative and potent 5-LO inhibitors
with fewer side effects continues.
A number of naturally-occurring compounds have been
investigated as potential inhibitors of 5-LO and LT biosynthesis.
Amongst these are polyhydroxylated products such as caffeic acid
and related compounds that are widely distributed in plants and
exhibit anti-oxidant [11–13] and anti-inflammatory properties
[14,15]. Synthetic caffeic acid analogues were recently shown to be
promising 5-LO inhibitors [14,16,17], while caffeic acid and its
naturally-occurring analogue, caffeic acid phenethyl ester (CAPE,
Figure 1), a component of propolis from honeybee hives, were
reported to inhibit LT production in mouse peritoneal macro-
phages [14].
Since many known 5-LO inhibitors, including zileuton [18],
function by reducing the catalytically-active ferric form of 5-LO,
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their structure-activity relationship as free radical scavengers,
antioxidants and 5-LO inhibitors. Both ester and amide analogues
of CAPE were designed with the rationale that esters may be more
susceptible to chemical and enzymatic degradation compared to
the corresponding amide. Since the hydroxyl groups within the
catechol moiety were reported to play an important role in several
biological activities [19], cinnamoyl analogues were also synthe-
sized to evaluate the effect of the presence of these functional
groups.
In this study, our results demonstrate that while these
compounds are effective antioxidants, certain structural features
were required for effective inhibition of LT biosynthesis.
Methods
Ethics
Blood was obtained from health volunteer subjects after having
obtained written consent. This research was approved by the
«Comite ´ d’e ´thique de la recherche avec les e ˆtres humains» at
Universite ´ de Moncton.
Synthesis of CAPE-like analogues
The synthesis of CAPE and its analogues is summarized in
Figure 2. The ester and amide analogues were synthesized from 2-
phenylethanol or 2-phenylethanamine with cinnamic acid, 2,o r
acetylated caffeic acid, 6. The conversion of 2 or 6 into the
corresponding carboxylic chloride was achieved by the Vilsmeier-
Haack adduct [20] derived from thionyl chloride (SOCl2) and
N,N-dimethylformamide (DMF) as catalyst. Base-induced de-O-
acetylation in 7 or 8 to afford CAPE (1) and the amide analogue,
9, was accomplished with potassium carbonate in methanol and
dichloromethane (Figure 2). NMR and mass spectrometry analyses
were found to be identical to those reported [21–24].
Isolation of PMNL from peripheral blood
PMNL were isolated from heparinized blood obtained from
healthy donors as previously described [25]. Briefly, blood was
centrifuged at 3006g for 5 min at room temperature, plasma was
collected and erythrocytes were removed by dextran sedimenta-
tion. Following centrifugation on a lymphocyte separation
medium cushion (density, 1.077 g/ml) (Wisent, St-Bruno, Qc,
Canada) at 9006 g for 20 min at room temperature, PMNL
(.96%) were obtained from the pellet after hypotonic lysis to
remove residual erythrocytes.
5-LO activity in a cell-free assay
Investigation of compounds as 5-LO inhibitors was performed
as described previously with minor modifications [16]. Briefly,
HEK293 cells (ATCC, Manassas, VA) (10
7 cells/ml) stably
transfected with 5-LO were incubated in a hypotonic buffer
(50 mM Tris-HCl pH 7.6, 150 mM NaCl, and 2 mM EDTA) for
10 min on ice. The cell mixture was then passed through a 21-
gauge needle 10 times. Cell lysates were vortexed and centrifuged
at 38006 g for 5 min at 4uC and the cell lysate supernatant
containing 5-LO was recuperated. Supernatants containing 5-LO
and 5 mM CaCl2 were then preincubated with each of the test
compounds at the indicated concentrations (see figure legends) for
5 min at 37uC. The 5-LO reaction was initiated by the addition of
1 mM ATP and 40 mM AA followed by incubation at 37uC for
20 min. Reactions were stopped by the addition of 0.5 volume of
cold MeOH:CH3CN (1:1) containing 50 ng of prostaglandin B2
(PGB2) as internal standard and samples were stored at 220uC
overnight to maximize protein denaturation. Samples were then
centrifuged at 10006 g for 10 min, the supernatant was diluted
with 4 volumes of acidified water (acetic acid, 0.1% v/v) and then
applied onto a preconditioned octadecyl (C18) column. Columns
containing samples were washed with 2 ml acidified water and 5-
LO products were eluted with 3 ml of methanol. After evaporation
of solvents with nitrogen, products were suspended in 20%
methanol and subjected to RP-HPLC analysis with diode array
detection as previously described [26]. Total 5-LO products
quantified represents the sum of LTB4, its trans isomers, 20-
COOH- and 20-OH-LTB4 and 5-hydroxyeicosatetraenoic acid.
Stimulation of PMNL for 5-LO products
Isolated PMNL (10
7 cells/ml) suspended in Hank’s balanced
salt solution (Lonza, Walkerville, MD) were pre-incubated with
compounds for 5 min at 37uC in the presence of 1.6 mM CaCl2
and 1 U/ml of adenosine deaminase (Sigma-Aldrich, Oakville,
On, Canada). Cells were then stimulated for 15 min at 37uC with
1 mM thapsigargin (Sigma-Aldrich) with or without 10 mMA A
(Cayman Chemical, Ann Arbour, MI) as previously described
[27]. Reactions were stopped by the addition of 0.5 volume of cold
MeOH:CH3CN (1:1) and 50 ng of PGB2 as internal standard and
samples were stored at 220uC until processing on octadecyl (C18)
columns and RP-HPLC analysis as indicated above.
Measurement of AA release
Isolated PMNL (10
7 cells/ml) were stimulated with 1 mM
thapsigargin as above but in the presence of 0.1% of BSA to
capture released AA and with a stimulation time of 5 min.
Stimulation was stopped by the addition of 2 volumes of cold
methanol, 300 ng octadeuterated-AA (Cayman Chemical) was
added as an internal standard and samples were stored at 220uC
overnight. Samples were centrifuged at 10006 g for 10 min and
supernatants were diluted with 8 volumes of acidified water for
processing on a preconditioned octadecyl (C18) as indicated above.
Samples were eluted with 3 ml of methanol, dryed under N2, and
pentafluorobenzylesters were prepared by adding 50 ml N,N-
diisopropylethylamine (20% in CH3CN)(Sigma-Aldrich) and 50 ml
2,3,4,5,6-pentafluorobenzyl bromide (20% in CH3CN)(Sigma-
Aldrich) [28]. After heating at 40uC for 40 min, samples were
dried under N2, resuspended in 100 ml hexane and AA was
measured by negative ion chemical ionisation gas chromatogra-
Figure 1. Molecular structures of CAPE 1 and zileuton.
doi:10.1371/journal.pone.0031833.g001
Figure 2. Summary of the synthesis of CAPE and its analogues.
doi:10.1371/journal.pone.0031833.g002
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Waltham, MA) and a Polaris Q mass spectrometer (Thermo).
Ex vivo whole blood stimulation
Zymosan stimulation of whole blood was performed as
previously described [29,30] with minor modifications. Each
compound or its diluent dimethyl sulfoxide (DMSO) was added to
1 ml heparinized blood obtained from healthy donors at the
indicated concentrations and incubated for 10 min at 37uCi na
water bath. Blood was then stimulated with the addition of 125 ml
of 40 mg/ml opsonised zymosan, gently vortexed and incubated
for 30 min at 37uC. Samples were then centrifuged for 10 min at
9606ga t4 uC. Plasma (350 ml) was removed and added to tubes
containing 1.2 ml of CH3OH:CH3CN (1:1) and 50 ng of PGB2 as
internal standard. Samples were stored overnight at 220uC and
then processed for RP-HPLC analysis of 5-LO products as
described above.
Determination of the antioxidant and radical scavenging
activity of test compounds
The antioxidant assay was performed as previously described
[31]. Briefly, a 5 mM phosphate-buffered solution (pH 7.4)
containing 0.05% Tween 20 (Sigma-Aldrich) and 0.16 mM
linoleic acid (Cayman Chemical) was preheated at 40uC. Test
compounds or their diluent (DMSO) were added to the mix at the
indicated concentrations (see figure legends). The oxidation
reaction, performed under a constant temperature of 37uC, was
initiated by adding 50 ml of a 2,29-azobis(2-amidinopropane)
dihydrochloride (AAPH) solution (10 mg/ml) (Cayman Chemical)
to 1 ml of the above solution. The rate of lipid oxidation was
determined by measuring the absorbance at 234 nm with a
Thermo Varioskan UV visible spectrophotometer every 5 min for
3 h. Inhibition of linoleic acid oxidation was calculated as
followed: (%) = (1 - rate absorbance change with test
compound/rate of absorbance change with solvent control)6100.
The free radical scavenging activity of test compounds was
measured as previously described using 2,2-Diphenyl-1-picrylhydra-
zyl (DPPH) as a stable radical [32,33]. 1 ml of DPPH in ethanol
(60 mM) was mixed with 1 ml of the test compounds at the indicated
concentrations or their diluent (ethanol). Each mixture was then
shaken vigorously and held in the dark for 30 min at room
temperature. The absorbance of DPPH at 520 nm was then
measured. The radical scavenging activity was expressed in terms
of % inhibition of DPPH absorbance (%inhibition = [(Acontrol2
Atest)/Acontrol)]6100) where Acontrol is the absorbance of the control
(DPPH solution without test compound) and Atest is the absorbance of
the test sample (DPPH solution plus compound). Ascorbic acid was
used as a reference compound.
Statistical analysis
Statistical analysis and graph design were performed with
GraphPad Prism 5 software (GraphPad Software, San Diego,
California). All data are expressed as mean 6 SEM. One sample t-
tests were performed to determine significant difference from
controls. IC50 values were calculated from a sigmoidal concentra-
tion-response curve-fitting model.
Results
The biosynthesis of 5-LO products in stimulated human
PMNL
A first series of experiments was performed in which PMNL
were stimulated with 1 mM thapsigargin in presence or absence of
10 mM AA. Under these conditions, the biosynthesis of 5-LO
products was 176 6 16 pmol/10
6 cells (mean 6 SEM) and
357633 pmol/10
6 cells (mean 6 SEM) for thapsigargin and
thapsigargin/AA, respectively. The effect of a fixed concentration
(1 mM) of the various test compounds on the biosynthesis of 5-LO
products was then measured (Figure 3). Stimulation of PMNL in
the presence of exogenous AA excludes the possibility that the test
compounds might affect LT biosynthesis by blocking AA
availability. In PMNL stimulated with thapsigargin in the presence
of exogenous AA, only CAPE 1 and zileuton significantly
decreased production of 5-LO products by 53% and 17%,
respectively (Figure 3A). A more significant decrease in the
biosynthesis of 5-LO products was observed when PMNL were
stimulated in the absence of exogenous AA. Under these
experimental conditions, 1 mM of CAPE 1, compound 9 and
zileuton inhibited the biosynthesis of 5-LO products by 85%, 20%
and 40%, respectively (Figure 3B). In concentration response
experiments in the absence of exogenous AA, CAPE 1 showed
potent inhibition of the biosynthesis of 5-LO products with an
IC50 value of 0.52 mM while its amide analogue compound 9 and
zileuton had IC50 values of 1.70 mM and 1.90 mM, respectively
(Figure 3C and Table 1).
5-LO activity in a cell-free assay
Since CAPE 1 and compound 9 inhibited LT biosynthesis in
stimulated whole cells, their ability to inhibit 5-LO activity was
investigated in a cell-free assay in HEK293 cells stably transfected
with 5-LO. 5-LO activity was effectively inhibited in the presence
of CAPE 1, compound 9 and zileuton. CAPE 1 was a more potent
5-LO inhibitor than compound 9 and zileuton with a measured
IC50 value that was an order of magnitude smaller (Figure 4 and
Table 1).
AA release from stimulated human PMNL
The inhibition of LT biosynthesis by CAPE 1 and compound 9
was more effective in the absence of exogenous AA. We therefore
investigated if these compounds might partially block LT
biosynthesis by inhibiting the release of AA from membrane
phospholipids, thus limiting substrate availability. Since zileuton
has been shown to inhibit AA release from mouse peritoneal
macrophages stimulated with zymosan [34], we investigated if our
test compounds could also impact on this key cellular event in the
biosynthesis of 5-LO products. When PMNL were pre-incubated
with the test compounds (1 mM), only CAPE 1 and zileuton
inhibited AA release by 56% and 37%, respectively, compared to
controls (Figure 5).
Biosynthesis of 5-LO products in stimulated whole blood
To investigate the ability of the compounds that showed
significant inhibition of LT biosynthesis in isolated PMN to inhibit
LT biosynthesis in a more complex and physiologically-relevant
environment, LT biosynthesis was measured ex vivo in stimulated
human blood. When whole blood was stimulated with zymosan in
the presence of 1 mM of the test compounds, CAPE 1 and the
reference molecule zileuton had similar effects, inhibiting LT
biosynthesis by 32% and 37%, respectively (Figure 6A). Dose-
response experiments confirmed the similar capacity of 5-LO
pathway inhibition by CAPE 1 (IC50=1.79 mM) and zileuton
(IC50=1.41 mM) while compound 9 did inhibit 5-LO product
biosynthesis at ahigher concentrations (IC50=4.93 mM) (Figure 6B
and Table 1). Importantly, in addition to thapsigargin stimulation
of isolated PMNL, the use of opsonized zymosan in these whole
blood experiments showed that the test compounds inhibit
leukotriene biosynthesis in leukocytes activated by different stimuli.
Leukotriene Inhibitors in Human Leukocytes
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One mechanism by which 5-LO can be inhibited is through
reductive inhibition of the ferric non-heme iron of the enzyme.
Compounds with anti-oxidant or free radical scavenging activity
can therefore be effective 5-LO inhibitors. An initial evaluation of
the reducing ability of the test compounds was determined by their
interaction with the stable free radical DPPH since free radical
scavengers can pair its free electron causing a stoichiometric
decrease in absorbance at 520 nm. All catechol compounds tested,
caffeic acid 5, CAPE 1 and compound 9, were efficient free radical
scavengers in with IC50 values in the low mM range as opposed to
their non-catechol analogues, cinnamic acid 2, compounds 3 and
4 that showed no scavenging activity at concentrations up to
100 mM (Figure 7A and Table 2). Zileuton was not a strong free
radical scavenger with an IC50 value of .100 mM while the
reference compound ascorbic acid showed an IC50 values of
75 mM.
Since CAPE 1 and zileuton have documented antioxidant
properties [13,18], we investigated if CAPE 1 and its amide
analogue compound 9 were better antioxidants than zileuton. As
shown in Figure 7B and Table 2, CAPE 1, compound 9, Zileuton
and caffeic acid all demonstrated similar antioxidant properties.
Discussion
In our ongoing effort to develop more potent inhibitors of
leukotriene biosynthesis, CAPE 1 and several of its analogues were
synthesized and compared to the reference molecule zileuton. The
present study focused on the inhibition of 5-LO and LT
biosynthesis in human PMNL as these cells are important
producers of the powerful chemoattractant LTB4 [35]. CAPE 1
was a more potent inhibitor than zileuton of 5-LO activity and of
LT biosynthesis in stimulated human PMNL, although its
inhibition of LT biosynthesis in whole blood was similar to that
of zileuton. CAPE 1 had been previously reported to inhibit a
plant lipoxygenase using linoleic acid as a substrate [13,33].
Unfortunately, the authors reported this activity to be that of 5-
LO. This was not the case since linoleic acid with its 9, 12 cis
double bond is not a 5-LO substrate and the product of the plant
lipoxygenase-catalyzed reaction, 9-hydroperoxy-10, 12-octadeca-
dienoic acid, is not a 5-LO product. 5-LO catalyzes the
abstraction of a pro-S hydrogen at the C-7 position of substrates
with 5, 8 cis double bonds, like arachidonic acid, followed by the
addition of molecular oxygen to form a 5-hydroperoxy-fatty acid
[36]. Therefore, the present study is the first report of the
inhibition of 5-LO activity by CAPE.
Several structural features of CAPE 1 were investigated for their
importance in the inhibition of LT biosynthesis and of 5-LO
activity. The phenethyl ester group of the molecule was essential
for effective inhibition since caffeic acid and cinnamic acid did not
show significant activity at concentrations up to 10 mM (data not
shown), and as previously reported in 5-LO-transfected HEK293
cells [16]. This result in human leukocytes is not consistent with
that reported in ionophore-stimulated murine peritoneal macro-
phages where both caffeic acid and CAPE show similar inhibition
of leukotriene synthesis [14]; the reason for this difference is not
apparent but the phenethyl moiety is clearly required for the
inhibition of both 5-LO activity and LT biosynthesis in human
Figure 3. Biosynthesis of 5-LO products by thapsigargin-
stimulated PMNL in the presence of various compounds. PMNL
incubated with 1 mM of the indicated compounds or their diluent
(Control, 0.5% DMSO) for 5 min were then stimulated with thapsigargin
(1 mM) for 15 min in the presence (A) or absence (B) of exogenous
arachidonic acid (10 mM). Dose-response of CAPE 1, compound 9 and
zileuton for the inhibition of the biosynthesis of 5-LO products (C).
Reactions were stopped by the addition of 0.5 volume of cold
MeOH:CH3CN (1:1) and samples were processed for measurement of
5-LO products by RP-HPLC. Total 5-LO products represent the sum of
LTB4, its trans isomers, 20-COOH- and 20-OH-LTB4 and 5-hydroxyeico-
satetraenoic acid. *Different from control, P,0.05, #different from
control, P,0.005. AA=cells incubated without thapsigargin stimulus.
Data are expressed as means 6 SEM of 3 to 5 independent
experiments, each performed in duplicate.
doi:10.1371/journal.pone.0031833.g003
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essential for activity as compounds 3 and 4 were without
inhibitory activity at concentrations up to 10 mM (not shown).
While compound 9 inhibited LT biosynthesis and 5-LO activity,
the presence of the amide linkage reduced its potency compared to
the ester CAPE 1 by approximately 3-fold for LT biosynthesis and
by 18-fold for the inhibition of 5-LO activity in cell lysates
(Table 1).
Human PMNL were stimulated in the presence or in the
absence of exogenous AA to evaluate the inhibition of LT
biosynthesis while bypassing the critical step of AA release from
phospholipids, or not. CAPE 1, zileuton and compound 9 were all
more effective inhibitors of LT biosynthesis in the absence of
exogenous AA suggesting that all three compounds inhibit the 5-
LO catalyzed conversion of AA to LTs. A cell-free 5-LO assay
using HEK293 cells that were stably transfected with 5-LO
confirmed that CAPE 1, zileuton and compound 9 all inhibited
the 5-LO-catalyzed conversion of AA to LTs, where CAPE 1
(IC50=0.13 mM) was 27-fold more active than zileuton for the
inhibition of 5-LO activity while compound 9 and zileuton showed
similar inhibitory activities.
It is well documented that human PMNL spontaneously release
significant amounts of adenosine when they are cultured in vitro
[37]. This build up is usually not observed in tissues and blood
since stromal cells and erythrocytes rapidly transport adenosine
into their cytosol [37,38]. This adenosine acts through G-protein
linked receptors to activate adenylate cyclase and increase cellular
cAMP levels [27,39]. In human PMNL, elevated cAMP reduces
numerous functional responses to agonist stimulation including
oxygen radical (superoxide) production, phagocytosis and leuko-
triene biosynthesis [27,37,38,40–42]. Therefore, freshly isolated
human PMNL will quite rapidly (within minutes) begin to lose
their capacity to respond to agonists unless the accumulation of
adenosine in cell culture is prevented. We routinely add ADA to
isolated PMNL incubations to prevent the inhibitory constraint of
adenosine [27,42–47] and although the possibility exists that
added ADA may interact with and impact on the test compounds
in the present study, this is unlikely since the inhibition of 5-LO
Figure 4. Impact of CAPE 1, compound 9 and zileuton on the
synthesis of 5-LO products in cell lysates. HEK293 cell lysate
supernatants were incubated with CAPE 1, compound 9, zileuton or
their diluent (Control, 0.5% DMSO). Synthesis of 5-LO products was
initiated by the addition of 40 mM AA and 1 mM ATP. Reactions were
stopped after 20 min by the addition of 0.5 volume of cold
MeOH:CH3CN (1:1) and samples were processed for measurement of
5-LO products by RP-HPLC. Total 5-LO products represent the sum of
LTB4, its trans isomers, 20-COOH- and 20-OH-LTB4, and 5-hydroxyeico-
satetraenoic acid. Values represent means 6 SEM of three independent
experiments, each performed in duplicate.
doi:10.1371/journal.pone.0031833.g004
Figure 5. Impact of CAPE 1, compound 9 and zileuton on AA
release by stimulated PMNL. PMNL were incubated with 1 mMo f
the indicated compounds or their diluent (Control, 0.5% DMSO) for
5 min and were then stimulated with thapsigargin (1 mM) or its diluent
(-thaps) for 5 min. Stimulation was stopped by the addition of
2 volumes of cold methanol containing octadeuterated-AA as an
internal standard. Samples were stored at -20uC overnight, AA was
extracted on octadecyl columns, pentafluorobenzylesters were pre-
pared and were measured by GC-MS. *Different from control, P,0.05.
Data are expressed as means 6 SEM of three independent experiments,
each performed in duplicate.
doi:10.1371/journal.pone.0031833.g005
Table 1. IC50 values for the inhibition of the synthesis of 5-LO products of test compounds in the different assays.
Compounds PMNL stimulation IC50 (mM) Cell lysate IC50 (mM) Whole blood IC50 (mM)
1 Mean 0.52 0.13 1.79
CI 0.44 to 0.61 0.08 to 0.23 1.45 to 2.20
zileuton Mean 1.90 3.54 1.41
CI 1.48 to 2.42 2.34 to 5.38 1.22 to 1.63
9 Mean 1.70 2.38 4.93
CI 1.21 to 2.38 1.43 to 3.95 3.42 to 7.10
Values are means from 3 independent experiments, each performed in duplicate.
CI=95% confidence interval.
doi:10.1371/journal.pone.0031833.t001
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preparations and in stimulated whole blood, two assay conditions
that were devoid of added ADA.
Since the 5-LO inhibitor zileuton was previously shown to also
inhibit AA release from membrane phospholipids in mouse
peritoneal macrophages [34], the release of free AA from PMNL
phospholipids was also measured following cell stimulation. CAPE
1 (1 mM) inhibited almost 55% of the AA released from membrane
phospholipids of stimulated human PMN compared to 35% of
inhibition with zileuton and no effect of compound 9. Since the
group IVA phospholipase A2 (cPLA2a) is responsible for AA
release in stimulated human PMNL [47,48], these results suggest
that both CAPE 1 and zileuton block LT biosynthesis in human
PMN by inhibiting the activation of cPLA2a as well as that of 5-
LO.
Many 5-LO inhibitors including zileuton [18] inhibit the
enzyme by reducing the catalytically-active ferric form of 5-LO.
Catechols as a class of compounds are known anti-oxidants and
can potentially inhibit 5-LO as free radical scavengers and
antioxidants. When the test compounds were evaluated for anti-
oxidant and free-radical scavenging activity, their potency was not
necessarily related to their ability to inhibit 5-LO. Not surprisingly,
cinnamic acid and its phenethyl ester and phenethyl amide
derivatives, compounds 3 and 4, showed no antioxidant or free
radical scavenging activity at concentrations up to 25 mM and
100 mM, respectively. However, caffeic acid, which showed no
inhibition of 5-LO, was as effective an antioxidant and free-radical
scavenger as CAPE 1 and compound 9. This suggests that
catechols may not efficiently reduce the ferric iron of 5-LO for
enzyme inhibition without the contribution of a hydrophobic
moiety that may act as an anchor to more specifically target the
non-heme iron of the 5-LO protein. Zileuton was also an effective
Figure 6. Impact of CAPE 1, compound 9 and zileuton on the
biosynthesis of 5-LO products in stimulated whole blood.
Whole blood incubated with 1 mM of the indicated compounds or their
diluent (Control, 0.5% DMSO) for 5 min was then stimulated with
opsonised zymosan (5 mg/ml) for 30 min (A). Dose-response for the
inhibition of 5-LO products of test compounds in opsonised zymosan-
stimulated whole blood (B). After stimulation, blood was centrifuged,
plasma was removed and added to 3.5 volumes of cold MeOH:CH3CN
(1:1) and samples were processed for measurement of 5-LO products by
RP-HPLC. Total 5-LO products represent the sum of LTB4, its trans
isomers, 20-COOH- and 20-OH-LTB4 and 5-hydroxyeicosatetraenoic
acid. *Significantly different from control, P,0.05, #Significant different
from control P,0.005. Data are expressed as means 6 SEM of 3
independent experiments, each performed in duplicate.
doi:10.1371/journal.pone.0031833.g006
Figure 7. Free radical scavenging and antioxidant activities of
various test compounds. (A) For free radical scavenging activity,
1 ml of DPPH (60 mM in ethanol) was mixed with 1 ml of the test
compounds or their diluent (DMSO) in ethanol. Solutions were held in
the dark for 30 min at room temperature and the absorbance was then
measured at 520 nm. The free radical scavenging activity was expressed
in terms of % inhibition of DPPH absorbance. (B) For antioxidant
activity, test compounds or their diluent (DMSO) were added to a
solution containing 0.16 mM linoleic acid and the oxidation reaction
was initiated by adding 50 ml AAPH solution (10 mg/ml) to 1 ml of the
above solution. The rate of lipid oxidation was determined by
measuring the increase in absorbance at 234 nm over a 3 h period.
Values represent the mean 6 SEM of 3 independent experiments, each
performed in triplicate.
doi:10.1371/journal.pone.0031833.g007
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scavenger.
The rationale for synthesizing amide-linked analogues was that
they may be more stable than ester-linked compounds, like CAPE
1, which could be susceptible to hydrolysis by esterases. Despite
being much more potent than zileuton and compound 9 at
inhibiting 5-LO activity in broken cell assays, and despite
inhibiting the release of AA from stimulated cells, CAPE 1 was
only moderately more effective than compound 9 at inhibiting LT
biosynthesis in stimulated human PMNL and in whole blood, and
was not different from zileuton in whole the blood assays. This
suggests that while remaining a potent inhibitor of LT biosynthe-
sis, the suspected susceptibility of CAPE 1 to esterases may reduce
its potency in a physiological setting.
In summary, we characterized CAPE 1, a naturally occurring
component of propolis from honeybee hives, as a potent inhibitor
of LT biosynthesis that acts as a dual inhibitor of 5-LO activity
and of AA release from membrane phospholipids. A continued
effort for the rational design of inhibitors of LT biosynthesis using
the CAPE 1 structure as framework may yield stable and potent
inhibitors of LT biosynthesis. Such rational design efforts will
certainly be aided by the recent description of the crystal structure
of the human 5-LO protein [49].
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